Aardvark Therapeutics, Inc. Common Stock AARD Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | —— | —— | —— | ||
| $57.75M+142% | $48.94M+182% | $42.7M— | $33.03M— | $23.91M— | ||
| $16.97M+137% | $13.79M+160% | $10.77M— | $7.83M— | $7.16M— | ||
| $74.72M+140% | $62.73M+175% | $53.47M— | $40.86M— | $31.08M— | ||
| -$74.72M-140% | -$62.73M-175% | -$53.47M— | -$40.86M— | -$31.08M— | ||
| $4.85M+44.2% | $5.13M+134% | $4.7M— | $4.22M— | $3.36M— | ||
| -$69.87M-152% | -$57.59M-180% | -$48.77M— | -$36.64M— | -$27.72M— | ||
| -$3.21+39.5% | -$2.93+43.1% | -$4.30— | -$4.60— | -$5.31— | ||
| -$74.68M-140% | -$62.69M-175% | -$53.44M— | -$40.83M— | -$31.07M— | ||
| -$74.72M-140% | -$62.73M-175% | -$53.47M— | -$40.86M— | -$31.08M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Aardvark Therapeutics, Inc. Common Stock profitable?
- Aardvark Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $69.9M over the trailing twelve months.
- What is Aardvark Therapeutics, Inc. Common Stock's earnings per share?
- Aardvark Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-3.21.
- Where does Aardvark Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Aardvark Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.